Belatacept: A new biological agent for maintenance immunosuppression in kidney transplantation

Expert Opinion on Biological Therapy

Volumn 12, Issue 7, 2012, Pages 965-979

  Arora, Swati ^a   Tangirala, Bhargavi ^a   Osadchuk, Liliana ^a   Sureshkumar, Kalathil K ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Acute rejection; Belatacept; Biological agents; Co stimulation blockers; Graft survival; Kidney transplantation; Post transplant lymphoproliferative disorder

Indexed keywords

ABATACEPT; ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EVEROLIMUS; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ANAPHYLAXIS; ANTIGEN PRESENTING CELL; AREA UNDER THE CURVE; ARTICLE; BASAL CELL CARCINOMA; BINDING AFFINITY; BRONCHITIS; CELLULAR IMMUNITY; CHEMICAL STRUCTURE; CHRONIC ALLOGRAFT NEPHROPATHY; COUGHING; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; EPSTEIN BARR VIRUS; FEVER; FLUSHING; FOLLOW UP; GASTROENTERITIS; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HEADACHE; HERPES SIMPLEX; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLUENZA; INJECTION SITE SWELLING; INTERMETHOD COMPARISON; KIDNEY ALLOGRAFT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; MEMORY T LYMPHOCYTE; NEOPLASM; PERIPHERAL EDEMA; POSTOPERATIVE PERIOD; QUALITY OF LIFE; RENAL PROTECTION; RHINOPHARYNGITIS; SIDE EFFECT; SKIN CARCINOMA; SURVIVAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THRUSH; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 84862212813     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.683522     Document Type: Article

References (61)

1. Wolfe R, Ashby V, Milford E, et al. Comparison of mortality in all patients on dialysis, Patients on dialysis awaiting transplantation, recipients of a first cadaveric transplant. N Engl J Med 1999;341:1725-30
2. Schnuelle P, Lorenz D, Trede M, et al. Impact of renal cadaveric transplantation on survival in end-stage renal failure: Evidence for reduced mortality risk compared with hemodialysis during long term follow up. J Am Soc Nephrol 1998;9(11):2135
3. Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients Annual report. Table 1.11b. Available from: Http://www.ustransplant.org/FastFacts.aspx# [Accessed 2 January 2012]
4. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in United States: A critical reappraisal. Am J Transplant 2010;11(10):2264-5
5. Meier-Kriesche HU, Schold JD, Srinivas TR. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004;4(3):378
6. Nankivelli BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349(24):2326-33
7. Kaplan B, Budde K. Lessons from the CAESAR study: Calcineurin inhibitorscan't live with them and can't live without them. Am J Transplant 2007;7(3):495-6
8. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody- mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010;90:68
9. Stegall MD, Park WD, Larson TS, et al. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 2011;11(4):698-707
10. Rapamune Package Insert. 5.12. De novo use of Rapamune without Cyclosporine
11. Flechner SM, Glyda M, Cockfiled S, et al. The ORION study: Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011;11(8):1633-4
12. Ekberg H, Bernasconi C, Noldeke J, et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the symphony study. Nephrol Dial Transplant 2010;25(6):2004-10
13. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin- inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. Lancet 2011;377:837-47
14. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporin sparing with mycophenolate mofetil daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant 2007;7:560-70
15. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001;71:1282-7
16. OPTN/SRTR Data as of October 1, 2010
17. Cooper JE, Wiseman AC. Novel immunosuppressive agents in kidney transplantation. Clin Nephrol 2010;73(5):333-43
18. Halloran PF. Immunosuppresive drugs for kidney transplantation. N Engl J Med 2004;351:2715-29
19. Martin S, Tichy E, Gabardi S. Belatacept: A novel biologic for maintenance immunosuppression after renal transplantation. Pharmacotherapy 2011;31(4):394-407
20. Weisman MH, Durez P, Hallegua D, et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol 2006;33:2162-6
21. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA 29Y (belatacept), a high- affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005;5(3):443-53
22. Latek R, Fleener C, Lamian V, et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation 2009;87(6):926-33
23. Nulojix-Package Insert, June 2011
24. Zhou Z, Shen J, Kaul S, et al. Belatacept population pharmacokinetics in renal transplant patients [abstract 1501]. Abstract presented at American Transplant Congress; May 2010.
25. Shen J, Block R, Townsend X, et al. Pharmacokinetics, pharmacodynamics and immunogenicity of belatacept in renal transplant patients [abstract 187026]. American transplant congress; May 2010
26. Latek R, Fleener C, Lamian V, et al. Assessment of belatacept mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation 2009;87:926-933s
27. Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of Belatacept in renal transplantation. Clin J Am Soc Nephrol 2010;21:1587-96. This article provides summary of long-term safety and efficacy of belatacept.
28. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353:770-81. First randomized, multicenter study demonstrating non-inferiority of belatacept as compared with CsA.
29. Vincent F, Charpentier B, Vanrenterghem Y, et al. A phase III study of Belatacept-based immunosuppression regimes versus Cyclosporine in renal transplant recipients (BENEFIT Study). Am J Transplant 2010;10(3):535-46.. Large randomized clinical trial that compared belatacept with CsA in standard criteria donor kidney transplant recepients.
30. Durrback A, Pestana JM, Pearson T, et al. A phase III study of Belatacept versus Cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT Study). Am J Transplant 2010;10:547-57.. Large randomized clinical trial that compared belatacept with CsA in extended criteria donor kidney transplant recepients.
31. Larsen C, Grinyo J, Medina-Pestana J, et al. Belatacept-based regimens versus a Cyclosporine A-based regimen in kidney transplant recipients: 2-Year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010;90:1528-35
32. Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: A phase iii study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012;12(3):630-9
33. Rostaing L, Neumayer HH, Reyes-Acevedo R, et al. Belatacept-versus Cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes. Clin J Am Soc Nephrol 2011;6:2696-704
34. Florman S, Bresnahan B, Chan L, et al. Three year outcomes in Black/African American kidney transplant recipients from BENEFIT and BENEFIT-EXT studies [abstract 1091]. Am Transplant Congress; Apr - May 2011
35. Dobbles F, Wong S, Joo S, Kalsekar A. Health-related quality of life after kidney transplantation: Results from Belatacept clinical trials [abstract 1099]. Am Transplant Congress; Apr - May 2011
36. Dobbles F, Wong S, You M and Kalsekar A. Patient reports of immunosuppressant related side-effects after kidney transplantation: Results from the Belatacept phase III clinical trial (BENEFIT) [abstract 1100]. Am Transplant Congress; Apr - May 2011
37. Larsen C, Bray R, Howard G, et al. Evaluation of donor-specific antibodies in kidney transplant with belatacept or cyclosporine based immunosuppression in BENEFIT and BENEFIT-EXT [abstract O-244]. Am Transplant Congress; Apr - May 2011
38. Ferguson R, Grinyo J, Vincenti F, et al. Immunosuppression with Belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011;11:66-76.. This is an important study that compared belatacept-based regimen with tacrolimus-based regimen in steroid avoiding protocols.
39. Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to a Belatacept-based regimen in renal transplant recipients: A randomized phase II study. Clin J Am Soc Nephrol 2011;6:430-9
40. Grinyo J, Nainan G, Rial M, et al. Renal function at 2 years in kidney transplant recipients switched from Cyclosporine or Tacrolimus to Belatacept: Results from the long-term extension of a phase II study [abstract 226]. Am Transplant Congress; Apr - May 2011
41. Bestard O, Cassis L, Cruzado JM, et al. Costimulatory blockage with mTor inhibition abrogates effector T-cell responses allowing regulatory T-cell survival in renal transplantation. Eur Soc Organ Transpl 2011;24:451-60
42. Vincenti F. Costimulation blockade in autoimmunity and transplantation. J Allergy Clin Immunol 2008;121:307-8
43. Bluestone JA. CTLA-4I g is finally making it: A personal perspective. Am J Transplant 2005;5:423
44. Bestard O, Cruzado JM, Mestre M, et al. Achieving donor specific hyporesponsiveness is associated with FOXP3+ regulatory T cell recruitment in human renal allograft infiltrates. J Immunol 2007;179:4901
45. Noris M, Casiraghi F, Todeschini M, et al. Regulatory T cells and T cell depletion: Role of immunosuppressive drugs. J Am Soc Nephrol 2007;18:1007
46. Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4+CD25+FoxP3+ regulatory T lymphocytes. Nat Med 2008;14:88
47. Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008;8:2086-96
48. Ruggenenti P, Perico N, Gotti E, et al. Sirolimus versus Cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given Alemtuzumab induction from chronic allograft injury. Transplantation 2007;84:956
49. Kirk AD, Mead S, Xu H, et al. Kidney transplantation using alemtuzumab induction and belatacept/sirolimus maintenance therapy [abstract 56]. Am Transplant Congress; Apr - May 2011
50. Grinyo J, Charpentier B, Pestana JM, et al. An integrated safety profile analysis of Belatacept in kidney transplant recipients. Transplantation 2010;90:1521-7; 51
51. Diaz JM, Gich I, Bonfill X, et al. Prevalence evolution and impact of cardiovascular risk factors on allograft and renal transplant patient survival. Transplant Proc 2009;41:2151
52. Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with Cyclosporine in kidney transplant Recipients (BENEFIT and BENEFIT-EXT Studies). Transplantation 2011;91:976-83
53. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997;63(7):977-83
54. Kramer BK, Montagnino G, Del Castillo D, et al. Efficacy and safety of tacrolimus compared with cyclosporine A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transplant 2005;20(5):968-73
55. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357(25):2562-75
56. Cheung CY, Chan HW, Liu YL, et al. Long-term graft function with tacrolimus and cyclosporine in renal transplantation: Paired kidney analysis. Nephrology (Carlton) 2009; 14(8):758-63
57. Opelz G, Dohler B; Collaborative Transplant Study. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009;87(6):795-802
58. Bristol-Myers Squibb. Pharmacokinetics, Safety and Immunogenicity of Single Doses of Belatacept Administered Subcutaneously to Healthy Subjects. ClinicalTrials.gov; NCT00569803. www. bms.com [Accessed 2 January 2012]
59. Libertiny G, Watson CJ, Gray DW, et al. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients. Br J Surg 2001;88:1330-4
60. Caillard S, Dharnidharka V, Agodoa L, et al. Post-transplant Lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005;80:1233-43
61. Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation 2005;80:193-7